Expert Interviews

Shannon N. Westin, MD, discusses how patient considerations for immunotherapy treatment involve evaluating individual health profiles, potential adverse effects, and the importance of personalized approaches to enhance treatment efficacy and patient quality of life.

Shannon N. Westin, MD, discusses how neoadjuvant treatment considerations for endometrial cancer can improve surgical outcomes and patient prognosis through the use of personalized, multidisciplinary approaches tailored to individual tumor characteristics.

Shannon N. Westin, MD, discusses the molecular classification of endometrial cancer.

Shannon N. Westin, MD, provides an overview of endometrial cancer to the Oncology Brothers.

The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.

Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.

Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.

The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.

Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.

Panelists discuss the National Comprehensive Cancer Network (NCCN) guidelines for first-line treatment of EGFR-mutant metastatic non–small cell lung cancer (NSCLC), emphasizing the recommended therapies and best practices for patient management.

Panelists discuss how minimal residual disease (MRD) testing in colorectal cancer (CRC) is facilitating the development of chemo-sparing strategies while maintaining effective control of residual disease.

Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.

Panelists discuss other adverse events associated with amivantamab and lazertinib beyond infusion-related reactions.

Panelists discuss how minimal residual disease (MRD) detection in colorectal cancer (CRC) is improving postsurgical treatment decision-making and enabling more effective monitoring of patient outcomes.

A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.

Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.

Following a comprehensive debate on the treatment of patients with non–small cell lung cancer, Edward Kim, MD, presents the winning team with the title of victors of this CancerNetwork® Face-Off event.

Continuing discussion on the treatment of patients with EGFR-mutated NSCLC, Sandip P. Patel, MD, discusses the role of EGFR TKIs without chemotherapy.

Focusing on data from the FLAURA2 study, Erminia Massarelli, MD, PhD, MS, outlines the role of EGFR TKI plus chemotherapy for patients with EGFR-mutated NSCLC.

Teams from University of California San Diego and City of Hope debate whether neoadjuvant therapies will replace surgery plus adjuvant treatment for patients with resectable NSCLC.